SignaBlok awarded NIAAA / NIH SBIR Phase I grant to test new approach to treatment of alcoholic liver disease

SignaBlok > News

SignaBlok > News

SignaBlok awarded NIAAA / NIH SBIR Phase I grant to test new approach to treatment of alcoholic liver disease

SignaBlok presented multiple applications of SCHOOL technology in drug discovery at the 2016 BIO International Convention

SignaBlok presented innovative approach to diagnostic imaging of atherosclerosis at the 2015 NHLBI Innovation Conference-West

Diagnostic Magnetic Resonance Imaging of Atherosclerosis in Apolipoprotein E Knockout Mouse Model Using Macrophage-Targeted Gadolinium-Containing Synthetic Lipopeptide Nanoparticles

Shen ZT, Zheng S et al. PLoS One. 2015

SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for rheumatoid arthritis at the 2015 ACR Annual Meeting

SignaBlok awarded NCI / NIH SBIR Phase I grant to test TREM-1 therapy for pancreatic cancer

SignaBlok presented preclinical data showcasing company’s peptide therapeutic programs in cancer, inflammation and autoimmune diseases at the 2015 Therapeutics Stream at the Essential Protein Engineering Summit (PEGS) Annual Meeting

SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new therapy for rheumatoid arthritis

Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy

Rojas MA, Shen ZT et al. Biochim Biophys Acta Mol Basis Dis. 2018

SignaBlok wins NHLBI / NIH SBIR Phase II grant to test SignaBlok’s ultra high sensitivity MRI contrast agents for atherosclerosis imaging in rodent and non-rodent animal models